Pain Management Drugs Market Thumbnail Image

2020

Pain Management Drugs Market

Pain Management Drugs Market Size, Share, Competitive Landscape and Trend Analysis Report by Drug Class,, Indication, Pain Type : Global Opportunity Analysis and Industry Forecast, 2019-2027

LS : Pharmaceuticals

Select an option
Author's: Ravi Telugunta| Komal Urde | Roshan Deshmukh
Publish Date:

Get Sample to Email

The global pain management drugs market was valued at $71,431.85 million in 2019, and is projected to reach $91,649.16 million by 2027, registering a CAGR of 3.8% from 2020 to 2027. 

Pain is a disturbing sensory and emotional sensation that results from tissue damage or disease. In addition, different disorders may cause discomfort, such as multiple sclerosis, osteoarthritis, stomach ulcer, chronic arthritis, fibromyalgia, diabetic neuropathy, and cancer. The length of pain ranges from acute pain for short term to chronic pain for long term. Acute pain can be mild and lasts for only a moment or for weeks, or months. Chronic pain is caused by aged bone & joint conditions, nerve damage, or injury. A variety of drugs are used to manage pain resulting from inflammation in response to tissue damage, chemical agents/pathogens (nociceptive pain) or nerve damage (neuropathic pain). Most drugs act by binding to protein targets on cell membranes and affecting biochemical processes of the body.

Pain-Management-Drugs-Market-2020-2027

Rise in geriatric population is the major factor that drives growth of the global pain management drugs market as aged people are more prone to suffer from joint pain and other chronic conditions. Moreover, surge in prevalence of chronic diseases, such as cancer, diabetic neuropathy, and osteoarthritis propels the market growth. Furthermore, rise in number of surgical procedures and rise in healthcare expenditure are expected to fuel growth of the pain management drugs market. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth.

COVID-19 pandemic, which started from Wuhan city of China, has widespread across the globe. This pandemic has disrupted growth in many economies across various domains. The COVID-19 outbreak is expected to impact the pain management drugs market in the initial phase of during the forecast period. The COVID-19 pandemic has stressed healthcare systems worldwide, so many clinics and pain services are no longer open for public services, owing to of safety measures imposed by governments. Subsequently, most chronic pain facilities were deemed non-urgent, both outpatient and elective interventional procedures were limited or stopped during the COVID-19 pandemic to minimize risk of the viral spread. Furthermore, during the latter half of the forecast period, demand for pain management drugs is expected to rise, owing to factors such as telemedicine, which has become an appropriate and effective way to offer necessary medical services to patients with chronic pain.

The global pain management drugs market is segmented on the basis of drug class, indication, and region. On the basis of drug class, the market is categorized into nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, anticonvulsants, anti-migraine agents, antidepressants, opioids, and nonnarcotic analgesics. On the basis of indication, it is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, and fibromyalgia, bone fracture, muscle sprain, acute appendicitis and other indications.  On the basis of pain type, it is segmented into chronic pain and acute pain. On the basis of region, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Pain Management Drugs Market
By Drug Class
Your browser does not support the canvas element.

Opiods is projected as one of the most lucrative segments.

Drug class segment review

By drug class, the opioids segment was the largest contributor to the market in 2019, owing to high efficiency of opioids to relieve pain in major chronic conditions. The anesthetics segment is anticipated to possess highest growth rate during the forecast period.

Pain Management Drugs Market
By Indication
Your browser does not support the canvas element.

Cancer pain is projected as one of the most lucrative segments.

Segment review

By indication, the neuropathic pain segment accounted for a majority of the market share in 2019, and is expected to exhibit a prominent growth rate during the forecast period. In addition, increase in presence of large patient population is the major factor that increases demand for drugs for the segment. Cancer pain and chronic back pain segments are expected to grow at the highest rate throughout the forecast period, owing to increase in number of surgeries globally and rise in prevalence of chronic diseases that lead to back pain. 

On the basis of pain type, the chronic pain segment was the largest contributor to the market growth in 2019, and is expected to grow at a CAGR of 3.9% during the forecast period.

Pain Management Drugs Market
By Pain Type
Your browser does not support the canvas element.

Chronic Pain is projected as one of the most lucrative segments.

North America accounted for majority of the pain management drugs market share in 2019, and is expected to remain dominant throughout the forecast period. This was attributed to large number of aging population and favorable regulatory conditions. Rise in number of drug abuse cases and addictive nature of opioids has decreased use of prescriptions for opioids in the region, leading to decline in opioid consumption for pain management. On the other hand, Asia-Pacific is expected to experience highest growth rate during the forecast period, mainly attributable to presence of larger patient pool and increase in healthcare expenditure in the region.

Some of the key players operating in the market include Novartis AG, Eli Lilly & Company, Abbott Laboratories, Endo Health Solutions, Inc., Purdue Pharma L.P., Pfizer, Inc., Mylan NV., Merck & Co. Inc., Johnson & Johnson, and GlaxoSmithKline Plc. The other prominent players in the value chain include Allergen Inc., Bayer AG, Bristol-Myers Squibb, Valeant Pharmaceuticals International Inc., Boehringer Ingelheim, Sorrento Therapeutics, WEX Pharmaceuticals, and Zynerba Pharmaceuticals.

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the global pain management drug market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the pain management drugs market growth is provided in the report.
  • The pain management drugs market forecast is studied from 2020 to 2027
  • Comprehensive quantitative analysis of the industry from 2019 to 2027 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the application and products of pain management used across the globe.
  • Key market players and their strategies have been analysed to understand the competitive outlook of the pain management drugs market.

Pain Management Drugs Market Report Highlights

Aspects Details
icon_5
By DRUG CLASS
  • NSAIDs
  • Anesthetics
  • Anticonvulsants
  • Anti-migraine Agents
  • Antidepressants
  • Opioids
  • Nonnarcotic Analgesics
icon_6
By INDICATION
  • Arthritic Pain
  • Neuropathic Pain
  • Cancer Pain
  • Chronic Back Pain
  • Postoperative Pain
  • Migraine
  • Fibromyalgia
  • Muscle sprain/strain
  • Bone fracture
  • Acute appendicitis
  • Others
icon_7
By PAIN TYPE
  • Chronic pain
  • Acute pain
icon_8
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (Japan, China, Australia, India, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
icon_9
Key Market Players

NOVARTIS INTERNATIONAL AG, PFIZER INC., MYLAN N.V., GLAXOSMITHKLINE PLC (GSK), JOHNSON & JOHNSON, PURDUE PHARMA L.P., ENDO HEALTH SOLUTIONS, INC. (ENDO INTERNATIONAL PLC.), ABBOTT LABORATORIES, ELI LILY AND COMPANY, MERCK & CO., INC.

Analyst Review

The demand for pain management drugs has increased rapidly over recent years. Pain can be caused due to various reasons such as chronic diseases, cancer, and surgeries. Thus, these segments are the largest contributors to the market growth. Presence of large geriatric population base, rise in global prevalence of cancer, and availability of pipeline drugs that pose to be promising treatment options for patients with chronic diseases contribute to growth of the market. 

However, patent expiration of major best-seller drugs such as pregabalin and duloxetine by Pfizer and Eli Lilly & Co., respectively, and availability of alternative therapies such as acupuncture, massage, and medical devices hamper the market growth.

Employment of pain management drugs is the highest in North America, owing to increase in adoption of these drugs, high prevalence of chronic diseases, and increase in disposable income of customers. In addition, presence of a large geriatric population and favorable regulatory & healthcare reforms such as the U.S. Patient Protection and Affordable Care Act of 2010 supplement the market growth. 

Although the use of pain management drugs in Asia-Pacific and LAMEA is low, the adoption rate is expected to increase, owing to rise in disposable income and surge in incidences of chronic diseases. China and India are potential markets in Asia-Pacific. Moreover, increase in R&D investments, upsurge in healthcare expenditure, and rise in government funding & initiatives propel the market growth in Asia-Pacific.
 

Author Name(s) : Ravi Telugunta| Komal Urde | Roshan Deshmukh
Frequently Asked Questions?

The total value of Pain Management Drugs market was $71,431.85 million in 2019.

The forecast period in the report is from 2020-2027.

The market value of Pain Management Drugs market in 2020 was $70,742.38 million.

The base year calculated is 2019 in the report.

The demand for pain management drugs has increased rapidly over recent years. Pain can be caused due to various reasons such as chronic diseases, cancer, and surgeries. Thus, these segments are the largest contributors to the market growth. Presence of large geriatric population base, rise in global prevalence of cancer, and availability of pipeline drugs that pose to be promising treatment options for patients with chronic diseases contribute to growth of the market.

Rise in geriatric population is the major factor that drives growth of the global pain management market as aged people are more prone to suffer from joint pain and other chronic conditions. Moreover, surge in prevalence of chronic diseases, such as cancer, diabetic neuropathy, and osteoarthritis propels the market growth. Furthermore, rise in number of surgical procedures and rise in healthcare expenditure are expected to fuel growth of the market. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth.

The growth % of the Pain Management Drugs market is 3.8%.

Opioids segment holds the maximum market share.

Loading Table Of Content...

Pain Management Drugs Market

Global Opportunity Analysis and Industry Forecast, 2019-2027